Cascone and colleagues highlight that the addition of ipilimumab to nivolumab plus chemotherapy “maintained an overall acceptable toxicity and allowed curative-intent surgery without adverse postoperative outcomes.”

“Oncology providers should recommend aerobic and resistance exercise during active treatment with curative intent,” and they “may recommend preoperative exercise for patients undergoing surgery for lung cancer,” say the guideline authors.

The presence of circulating tumor DNA following treatment with curative intent for early-stage non-small-cell lung cancer is associated with an increased risk for relapse or death, LUCID study data show.

The cohort study, by Daniel Tan (National Cancer Centre Singapore) and colleagues, included 723 patients diagnosed with stage IA to IIIA NSCLC between 2010 and 2018 who underwent surgery with curative intent with or without adjuvant radiation and/or platinum doublet chemotherapy.

Data form the international COVIDSurg collaborative study show that around one in seven patients did not undergo planned surgery for cancer if their region was in full COVID-19 lockdown.

Despite the high mortality of non-small cell lung cancer, surgery and radiotherapy with curative intent can be offered if the disease is caught at an early stage.

All participants then underwent surgery between 2 and 6 weeks after the last dose of study treatment.

In the RATIONALE 307 study, 360 patients with stage IIIB (33.9%) or IV (66.1%) disease that was not amenable to curative surgery or radiotherapy were randomly assigned to receive intravenous tislelizumab 200 mg every 3 weeks alongside paclitaxel 175 mg/m 2 on day 1 or nab-paclitaxel 100 mg/m 2 on days 1, 8, and 15 plus carboplatin AUC 5 on day 1, or the paclitaxel–carboplatin combination alone.

Mammographic breast density is independently associated with lymphedema risk in women who undergo curative surgery for breast cancer and could be added to established risk factors to predict lymphedema severity, say researchers.

“Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group JAMA 2021; 325 : 962–970 JAMA 2021; 325 : 971–987 JAMA 2021; 325 : 988–997 JAMA 2021; 325 : 939–941

Timothy Hanna (Queen’s University, Kingston, Ontario, Canada) and co-authors focused on “high validity studies” that reported on treatment delays and survival across all three curative modalities – namely surgery, systemic therapy, and radiotherapy – in the radical, neoadjuvant, or adjuvant setting for cancers of the bladder, breast, colon, rectum, lung, cervix, and head and neck.

Describing the pCR benefit as “clinically meaningful,” the study presenter commented that “this new combination may offer an improved curative option for this patient population with a high unmet medical need.”

The primary aim of the trial was to investigate the efficacy of adjuvant genomically directed therapy versus physician’s choice of treatment in TNBC patients who had residual disease after neoadjuvant therapy and surgery.

Curative-intent surgery for early-stage non-small-cell lung cancer results in better long-term overall survival than stereotactic body radiotherapy, particularly when combined with an appropriate degree of regional lymph node examination, researchers report.

The study recruited 62 men with rising prostate-specific antigen (PSA) levels and no more than three extracranial metastatic sites after primary curative treatment, and randomly assigned them to undergo MDT – either surgery or stereotactic body radiotherapy – or surveillance.

This is a phase 2 trial comparing metastasis-directed therapy (MDT), either surgery or stereotactic body radiotherapy, and surveillance for prostate cancer patients with oligometastatic recurrent disease after primary curative therapy.

medwireNews : The US FDA has approved use of the PD-1 inhibitor cemiplimab-rwlc for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced disease who are unable to undergo surgery or radiotherapy with curative intent.

Oxaliplatin-based hyperthermic intraperitoneal chemotherapy after cytoreductive surgery does not improve the survival of colorectal cancer patients with peritoneal carcinomatosis, the PRODIGE 7 investigators report.

We cover three studies of colorectal cancer surveillance, one evaluating the relationship between adenomas at colonoscopy and the long-term incidence of cancer, while the other two investigate whether higher-intensity post-surgery follow-up improves outcomes.